Cancer types
  • Head and neck
Title of study
A randomized study with cisplatinum or cetuximab and standard or adaptive high dose radiotherapy for advanced head and neck cancer
Version Number
Approval Date 
6.0, 19 March 2014
Short Title
Artforce
Study site
Principle Investigator
Prof. Dr. H. Bartelink (NKI-AVL)
Investigator Maastro
Dr. F.J.P. Hoebers
Sponsor
WHO Trial Registry
DUCG
ClinicalTrials.gov
Objectives 

• Quality of life during and after treatment, at 6 months and 1 yr.
• Swallowing function preservation at 1 yr.
• Progression-free survival
• Overall survival

Primary Endpoint 

• Locoregional recurrence-free survival at 2 years.
• Correlation of anatomical distribution of 89ZR-cetuximab uptake with treatment arm and anatomical location of recurrence
• Toxicity
• The first interim-analysis is planned when one-third of the required number of events has been observed and the second analysis at two-third of the events

Secondary Endpoints